Every version by contractor
Open a version for its full policy text, contracts, codes and related NCDs. Covered codes are the count of ICD-10-CM codes in the version's billing and coding article; a dash means the export attaches no coded article.
Lineage
The Medicare Coverage Database records the source policy a determination was derived from: L33591 from L28463; L34063 from L31894. A shared source explains why the opening paragraphs read alike; the revision dates and the diagnosis counts above show where the versions have since parted.
Which diagnoses each contractor covers
Across the 2 versions with a coded billing and coding article, 1,034 ICD-10-CM codes are covered by at least one contractor: 344 by every version and 690 (67%) by only some of them. L33591 (Wellpoint Federal) covers the most codes no other version lists (664). L34063 (CGS Administrators, LLC) leaves out the most codes that every other version covers (664), the version where a diagnosis accepted elsewhere is most often absent. The comparison is mechanical: it counts codes on the lists and does not weigh the policy text, frequency limits or documentation rules, which can matter as much as the list.
Unique codes appear on that version's covered list only; missing codes are covered by every other version but not by this one. Lists are the union of the coded billing and coding articles linked to each LCD (MCD release 2026-11-12).
Where the lists part
Three-character ICD-10-CM categories ranked by how many of their codes are covered by some versions and not others; a category near the top is where checking the local list matters most.
| Category | Category title (FY2027) | Codes that differ |
|---|---|---|
| T63 | Toxic effect of contact with venomous animals and plants | 281 |
| T43 | Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified | 58 |
| T50 | Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances | 36 |
| T45 | Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified | 30 |
| T78 | Adverse effects, not elsewhere classified | 30 |
| T38 | Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified | 26 |
| T40 | Poisoning by, adverse effect of and underdosing of narcotics and psychodysleptics [hallucinogens] | 23 |
| T44 | Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system | 23 |
| T46 | Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system | 23 |
| T48 | Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system | 22 |
| T36 | Poisoning by, adverse effect of and underdosing of systemic antibiotics | 21 |
| T47 | Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system | 21 |
Code-by-contractor sample
100 of the 690 codes covered by some versions and not others, codes that most versions cover first and no more than three per category in the first pass. Y means the version's covered list includes the code.
| ICD-10-CM | Description (FY2027) | L33591 | L34063 |
|---|---|---|---|
| L50.9 | Urticaria, unspecified | Y | — |
| T36.0X5D | Adverse effect of penicillins, subsequent encounter | Y | — |
| T36.0X5S | Adverse effect of penicillins, sequela | Y | — |
| T36.1X5D | Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter | Y | — |
| T36.1X5S | Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela | Y | — |
| T36.2X5D | Adverse effect of chloramphenicol group, subsequent encounter | Y | — |
| T36.2X5S | Adverse effect of chloramphenicol group, sequela | Y | — |
| T36.3X5D | Adverse effect of macrolides, subsequent encounter | Y | — |
| T36.3X5S | Adverse effect of macrolides, sequela | Y | — |
| T36.4X5D | Adverse effect of tetracyclines, subsequent encounter | Y | — |
| T36.4X5S | Adverse effect of tetracyclines, sequela | Y | — |
| T36.5X5D | Adverse effect of aminoglycosides, subsequent encounter | Y | — |
| T36.5X5S | Adverse effect of aminoglycosides, sequela | Y | — |
| T36.6X5D | Adverse effect of rifampicins, subsequent encounter | Y | — |
| T36.6X5S | Adverse effect of rifampicins, sequela | Y | — |
| T36.7X5D | Adverse effect of antifungal antibiotics, systemically used, subsequent encounter | Y | — |
| T36.7X5S | Adverse effect of antifungal antibiotics, systemically used, sequela | Y | — |
| T36.8X5D | Adverse effect of other systemic antibiotics, subsequent encounter | Y | — |
| T36.8X5S | Adverse effect of other systemic antibiotics, sequela | Y | — |
| T36.95XA | Adverse effect of unspecified systemic antibiotic, initial encounter | Y | — |
| T36.95XD | Adverse effect of unspecified systemic antibiotic, subsequent encounter | Y | — |
| T36.95XS | Adverse effect of unspecified systemic antibiotic, sequela | Y | — |
| T37.0X5D | Adverse effect of sulfonamides, subsequent encounter | Y | — |
| T37.0X5S | Adverse effect of sulfonamides, sequela | Y | — |
| T37.1X5D | Adverse effect of antimycobacterial drugs, subsequent encounter | Y | — |
| T37.1X5S | Adverse effect of antimycobacterial drugs, sequela | Y | — |
| T37.2X5D | Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter | Y | — |
| T37.2X5S | Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela | Y | — |
| T37.3X5D | Adverse effect of other antiprotozoal drugs, subsequent encounter | Y | — |
| T37.3X5S | Adverse effect of other antiprotozoal drugs, sequela | Y | — |
| T37.4X5D | Adverse effect of anthelminthics, subsequent encounter | Y | — |
| T37.4X5S | Adverse effect of anthelminthics, sequela | Y | — |
| T37.5X5D | Adverse effect of antiviral drugs, subsequent encounter | Y | — |
| T37.5X5S | Adverse effect of antiviral drugs, sequela | Y | — |
| T37.8X5D | Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter | Y | — |
| T37.8X5S | Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela | Y | — |
| T37.95XA | Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter | Y | — |
| T37.95XD | Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter | Y | — |
| T37.95XS | Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela | Y | — |
| T38.0X5D | Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter | Y | — |
| T38.0X5S | Adverse effect of glucocorticoids and synthetic analogues, sequela | Y | — |
| T38.1X5D | Adverse effect of thyroid hormones and substitutes, subsequent encounter | Y | — |
| T38.1X5S | Adverse effect of thyroid hormones and substitutes, sequela | Y | — |
| T38.2X5D | Adverse effect of antithyroid drugs, subsequent encounter | Y | — |
| T38.2X5S | Adverse effect of antithyroid drugs, sequela | Y | — |
| T38.4X5D | Adverse effect of oral contraceptives, subsequent encounter | Y | — |
| T38.4X5S | Adverse effect of oral contraceptives, sequela | Y | — |
| T38.5X5D | Adverse effect of other estrogens and progestogens, subsequent encounter | Y | — |
| T38.5X5S | Adverse effect of other estrogens and progestogens, sequela | Y | — |
| T38.6X5D | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter | Y | — |
| T38.6X5S | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela | Y | — |
| T38.7X5D | Adverse effect of androgens and anabolic congeners, subsequent encounter | Y | — |
| T39.015D | Adverse effect of aspirin, subsequent encounter | Y | — |
| T39.015S | Adverse effect of aspirin, sequela | Y | — |
| T39.095D | Adverse effect of salicylates, subsequent encounter | Y | — |
| T40.0X5D | Adverse effect of opium, subsequent encounter | Y | — |
| T40.0X5S | Adverse effect of opium, sequela | Y | — |
| T40.2X5D | Adverse effect of other opioids, subsequent encounter | Y | — |
| T41.0X5D | Adverse effect of inhaled anesthetics, subsequent encounter | Y | — |
| T41.0X5S | Adverse effect of inhaled anesthetics, sequela | Y | — |
| T41.1X5D | Adverse effect of intravenous anesthetics, subsequent encounter | Y | — |
| T42.0X5D | Adverse effect of hydantoin derivatives, subsequent encounter | Y | — |
| T42.0X5S | Adverse effect of hydantoin derivatives, sequela | Y | — |
| T42.1X5D | Adverse effect of iminostilbenes, subsequent encounter | Y | — |
| T43.015D | Adverse effect of tricyclic antidepressants, subsequent encounter | Y | — |
| T43.015S | Adverse effect of tricyclic antidepressants, sequela | Y | — |
| T43.025D | Adverse effect of tetracyclic antidepressants, subsequent encounter | Y | — |
| T44.0X5D | Adverse effect of anticholinesterase agents, subsequent encounter | Y | — |
| T44.0X5S | Adverse effect of anticholinesterase agents, sequela | Y | — |
| T44.1X5D | Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter | Y | — |
| T45.0X5D | Adverse effect of antiallergic and antiemetic drugs, subsequent encounter | Y | — |
| T45.0X5S | Adverse effect of antiallergic and antiemetic drugs, sequela | Y | — |
| T45.1X5D | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter | Y | — |
| T46.0X5D | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter | Y | — |
| T46.0X5S | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela | Y | — |
| T46.1X5D | Adverse effect of calcium-channel blockers, subsequent encounter | Y | — |
| T47.0X5D | Adverse effect of histamine H2-receptor blockers, subsequent encounter | Y | — |
| T47.0X5S | Adverse effect of histamine H2-receptor blockers, sequela | Y | — |
| T47.1X5D | Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter | Y | — |
| T48.0X5D | Adverse effect of oxytocic drugs, subsequent encounter | Y | — |
| T48.0X5S | Adverse effect of oxytocic drugs, sequela | Y | — |
| T48.1X5D | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter | Y | — |
| T49.0X5D | Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter | Y | — |
| T49.0X5S | Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela | Y | — |
| T49.1X5D | Adverse effect of antipruritics, subsequent encounter | Y | — |
| T50.0X5D | Adverse effect of mineralocorticoids and their antagonists, subsequent encounter | Y | — |
| T50.0X5S | Adverse effect of mineralocorticoids and their antagonists, sequela | Y | — |
| T50.1X5D | Adverse effect of loop [high-ceiling] diuretics, subsequent encounter | Y | — |
| T63.011D | Toxic effect of rattlesnake venom, accidental (unintentional), subsequent encounter | Y | — |
| T63.011S | Toxic effect of rattlesnake venom, accidental (unintentional), sequela | Y | — |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter | Y | — |
| T78.00XD | Anaphylactic reaction due to unspecified food, subsequent encounter | Y | — |
| T78.00XS | Anaphylactic reaction due to unspecified food, sequela | Y | — |
| T78.01XD | Anaphylactic reaction due to peanuts, subsequent encounter | Y | — |
| T88.59XA | Other complications of anesthesia, initial encounter | — | Y |
| T88.6XXD | Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounter | Y | — |
| T88.6XXS | Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela | Y | — |
| Z91.0111 | Allergy to milk products with tolerance to baked milk | — | Y |
| Z91.0112 | Allergy to milk products with reactivity to baked milk | — | Y |
| Z91.0120 | Allergy to eggs, unspecified | — | Y |
Download every covered code with a column per LCD (CSV). The LCD coverage variation report ranks every multi-contractor title by how far its lists diverge.
How to use the comparison
Start from the state where the service is furnished and open that contractor's version; its billing and coding article carries the diagnosis codes the claims system will test. For a group that bills in several jurisdictions, the version with the smallest covered list is the safe common denominator for pre-service review, and the version with the largest list shows what documentation can support an appeal elsewhere. The L33591 version is the one most searched for this title; the LCD lookup guide explains how jurisdictions are assigned, and the LCD hub lists every topic that more than one contractor has written.
For teams evaluating QuickIntell software
Where QuickIntell fits across jurisdictions
For teams working across MAC jurisdictions, evaluate how requirements, source policies and documentation review should be organized for each case. Confirm jurisdiction-specific scope and supported actions during a QuickAuth evaluation; compare claim and denial follow-up separately in QuickRCM.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
Why are there 2 LCDs called "RAST Type Tests"?
Each Medicare Administrative Contractor writes its own Local Coverage Determination for its jurisdiction. 2 contractors publish a policy with this title covering 12 states; they often start from one contractor's text and then revise separately, so dates, criteria and diagnosis lists differ by jurisdiction.
Which "RAST Type Tests" LCD applies to my claim?
The one written by the contractor that processes the claim: the A/B MAC for the state where the service is furnished, or the DME MAC region for equipment. The table lists each policy's states; open the policy for that jurisdiction and its billing and coding article.
How different are the diagnosis lists?
Across the 2 versions with a coded billing and coding article, 1,034 ICD-10-CM codes are covered by at least one contractor: 344 by every version and 690 (67%) by only some of them. A diagnosis accepted under one contractor's version can deny under another's, so a group that bills in several jurisdictions checks the list of the contractor that processes each claim.
When were these policies last revised?
Revision effective dates run from 2026-04-01 to 2026-07-30. A claim is judged against the version in force on the date of service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
Disclaimer
Policy metadata and code counts are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.